Capecitabine is generally required to be taken for at least two courses of treatment, specifically depending on the individual's condition and under the guidance of a physician. Capecitabine tablets are a new type of targeted cancer drug that can effectively inhibit tumor metastasis, reduce the activity of cancer cells, and extend the lifespan of cancer patients. This medication is primarily used to treat cancer patients in the late stage who cannot undergo surgery or patients with metastatic gastric cancer.
1. Capecitabine tablets are a new type of selective targeted oral anti-cancer drug, with capecitabine as its main ingredient. It can inhibit tumor metastasis, significantly reduce the activity of cancer cells, and prolong the time period of cell division and proliferation. Clinical use has found that the spread of cancer cells in patients is significantly slower, effectively extending the lifespan of patients. It is suitable for the treatment of late-stage or metastatic gastric cancer that cannot be surgically treated.
2. Course of treatment is a medical term referring to the extent to which the condition has improved after a certain period of medication, followed by the determination of a new treatment plan. Patients take capecitabine tablets for two weeks of treatment, followed by a week of rest, with three weeks constituting one course of treatment. Patients should take the medication for at least six weeks and under the guidance of a physician.
3. Patients taking capecitabine tablets should not arbitrarily increase or decrease the drug dosage, nor should they extend the course of treatment or stop the medication suddenly.
4. Gastric cancer patients who experience nausea, abdominal distension, or other discomfort after eating should reduce or stop eating. They should resume eating once the symptoms disappear and the condition improves.
